RavenQuest BioMed Expands Geographical Production Footprint


Ryan Allway

June 19th, 2018

Exclusive, News, Top News


Canada’s upcoming legalization of recreational cannabis could put pressure on cannabis supply, according to a variety of sources, even as many licensed producers ramp up production capacity. Deloitte analysts project that the market could top C$22.6 billion over the coming years, driven by both domestic growth from recreational legalization and growing demand for export from the European Union and other countries around the world.

RavenQuest BioMed Inc. (CSE: RQB) is well-positioned to capitalize on these trends with its four-pillar approach to the industry and rapidly growing production portfolio. After moving to acquire another late-stage applicant earlier this month, investors may want to take a closer look at the stock over the coming months.

Western Agripharma Acquisition

RavenQuest BioMed recently announced a binding letter of intent to acquire Western Agripharma Ltd. and a 15-acre parcel of land for 4,335,294 common shares at $0.85 per share, or roughly $3.7 million in consideration. Management intends to apply its proprietary grow methodologies – Orbital Gardens – to the facility to dramatically increase the grams-per-square-foot production and unlock significant value in the transaction.

Western Agripharma is a late-stage applicant to become a licensed producer under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). With a 125,000 purpose-built facility in British Columbia’s Sunshine Coast, Western Agripharma will have an annual production capacity of about 25,000 kilograms and increase RavenQuest BioMed’s total capacity to about 51,000 kilograms per year once everything is in operation.

In addition to the 125,000 sq. ft. facility, Western Agripharma also owns a 23.75 percent stake in Atlantic Cannabis Corp., which intends to build a 50,000 sq. ft. facility and holds an additional 120 acre property in early stage application on Nova Scotia’s Cape Breton Island. This opportunity represents a longer-term opportunity in the cannabis industry, but offers additional production capacity that is geographically diversified.

Building a Presence Across Canada

The move to acquire Western Agripharma – and part of Atlantic Cannabis Corp. – is part of the RavenQuest BioMed’s long-term plan to expand its geographic footprint throughout Canada. Once the deal is completed, the company will have state of the art licensed facilities in Ontario, Alberta, and British Columbia, which represent three of the most dynamic markets in Canada for the cannabis industry given their population sizes and usage patterns.

“This acquisition adds the important British Columbia market to our growing presence in key markets across Canada,” said RavenQuest BioMed CEO George Robinson. “RavenQuest will have state of the art licensed cannabis facilities in Ontario, Alberta and British Columbia … The Western Agripharma facility will produce 25,000 kilograms annually, meaning RavenQuest’s planned projects will combine to produce 51,000 kilograms annually at build out.”

The acquisition strategy is also just one of the company’s four-pillar approach to the industry, which includes Indigenous People’s partnerships, investments in near-term cultivation, immediate revenue from management services, and ongoing research. Management has reported progress across all of these pillars over the past several quarters and the latest LOI to acquire a new late-stage applicant underscores these developments.

Looking Ahead

RavenQuest BioMed Inc. (CSE: RQB) represents a compelling investment opportunity in Canada’s burgeoning cannabis market. With its latest acquisition of a late-stage applicant, the company has both increased its planned production capacity and diversified its geographical footprint. These developments are only just the latest of many developments towards scaling up its four-pillar approach to the cannabis industry.
For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading